Synlogic, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mary Beth Dooley
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 301 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Sep 30, 2015
- CIK
- 0001527599
- Website
- synlogictx.com
- Similar Companies
- Business
- Synlogic, Inc. (Nasdaq: SYBX) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes synthetic biotics, which are orally administered, engineered microbial therapeutics designed to treat rare metabolic diseases, enteric hyperoxaluria, immuno-oncology indications including solid tumors, inflammatory bowel disease and other disorders; its pipeline includes lead candidates such as SYNB1934 and SYNB1618 for phenylketonuria (PKU), SYNB1353 for homocystinuria (HCU), SYNB8802 for enteric hyperoxaluria, and SYNB2081 for gout by lowering uric acid levels, as well as preclinical programs targeting gout and inflammatory bowel disease (IBD). Founded in 2013 and headquartered in Cambridge, Massachusetts, the company operates primarily in the United States within the biotechnology sector, focusing on synthetic biology platforms that leverage microbial strains for targeted metabolic and immunological interventions, with a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for IBD research under which it earned a $2.5 million milestone payment, and a partnership with Ginkgo Bioworks, Inc. Recent developments include the discontinuation of the Phase 3 Synpheny-3 study for its PKU candidate SYNB1934 in February 2024 following a failed trial, a subsequent 90% workforce reduction, CEO transition, an $80 million funding round in April 2024, and in August 2025, a $150 million mixed shelf filing to pursue strategic alternatives such as mergers, acquisitions, collaborations or potential dissolution amid a pivot to monetize its synthetic biology platform and remaining assets with $47.7 million in cash reserves.
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic Reports Second Quarter 2024 Financial Results
The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits
Synlogic Reports First Quarter 2024 Financial Results
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
Synlogic Adopts Limited Duration Stockholders Rights Plan
Why Is Synlogic (SYBX) Stock Down 55% Today?
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
Synlogic Provides Corporate Update and Outlook for 2024
Synlogic Announces Contract with the Air Force Research Lab
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
Why Is Synlogic (SYBX) Stock Down 6% Today?
Synlogic Announces Reverse Stock Split